Skip to content
Apex Circle

The Zimbabwean Government Turns Down ‘Lopsided’ US Healthcare Assistance Package Because of Data Apprehensions

Medical funding illustration
The proposed US funding would have supported initiatives for HIV/Aids treatment and prevention, TB, and malaria.

Zimbabwe has rejected a significant American healthcare agreement valued at 367 million US dollars (£272m) spanning five years because of Washington's request for sensitive information.

The decision became public following a government memo dated December was leaked, indicating that President Emmerson Mnangagwa deemed the agreement was "unbalanced".

An official representative has since clarified that the US was demanding access to biological samples for research and commercial purposes but was not willing to guarantee the resulting advantages from future treatments.

"We are forced to start the difficult and regrettable process of ending our support in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont in a statement.

The US Embassy noted the United States had donated over $1.9bn as health assistance to Zimbabwe during the past twenty years.

A medical body in Zimbabwe has urged continued talks to find a deal agreeable to both sides so the country's critical HIV treatment initiative can proceed.

Wider Implications

This rejection follows a comparable case in Kenya, where a high court blocked a related health funding agreement after concerns were raised about the security of citizens' medical information.

After resuming office recently, US President Donald Trump has drastically cut overseas assistance and closed the key foreign aid agency.

The agency had overseen assistance for the US government, but Trump argued its spending was "wasteful" and his administration was seeking government-to-government agreements to enhance openness and accountability.

As per reports, Sixteen nations in Africa have to date signed these new agreements, constituting more than $18.3bn in committed funds.

Details of the Rejected Deal

The funds for Zimbabwe would have gone towards "combating HIV/Aids, tuberculosis, malaria, healthcare for mothers and children, and preparing for epidemics".

"It is our view this collaboration would have delivered extraordinary benefits for Zimbabwean communities, particularly the 1.2 million presently receiving antiretroviral therapy via US-supported programmes," the Ambassador commented.

However, government spokesperson Nick Mangwana said the proposed deal was "asymmetrical".

"The proposal required Zimbabwe to share its biological resources and data for a long time, without any corresponding assurance of benefiting from any medical innovations – like new medicines or tests – that could result from that shared data," he stated.

"Effectively, our nation would provide the raw materials for medical research with no assurance that the final treatments would be available to our people if a future disease outbreak arise."

National Interest and Global Health

Mangwana further noted that the US's withdrawal from the global health body and its push of bilateral health agreements were disrupting frameworks previously set up via the global health agency.

Mangwana gave as an example its Pathogen Access and Benefit Sharing framework created to manage potential global health emergencies.

"This framework is designed to ensure that when a nation provides its information, the resulting advantages – including medicines and cures – are distributed fairly, not monopolised exclusively by those with the resources to develop them."

Zimbabwe's reservations over the US deal "must not be interpreted as anti-American sentiment," Mangwana stressed.

"We encourage further discussions with our US partners on how future co-operation could be arranged in a way that respects the sovereignty and interests of both nations."

Health Experts Reaction

A leading public health body stated it recognised the government's concerns, but recommended that negotiations should continue since much of the country's HIV programmes were funded by external financing.

"If specific concerns arise, such as those involving data governance or agreement terms, these can often be resolved through detailed discussion and negotiated safeguards," the group added.

The halted deal emphasises the ongoing debate between receiving much-needed international aid and safeguarding a country's data in an ever more data-driven world.

The writer

Douglas White

Maya Chen is a Toronto-based business strategist with over 15 years of experience in scaling startups and advising entrepreneurs across Canada.

Apex Circle

Type to search articles.